EP1003480A4 - Mit peptiden konjugierte nukleinsäuren mit erhöhter aufnahme in zellen - Google Patents

Mit peptiden konjugierte nukleinsäuren mit erhöhter aufnahme in zellen

Info

Publication number
EP1003480A4
EP1003480A4 EP98923819A EP98923819A EP1003480A4 EP 1003480 A4 EP1003480 A4 EP 1003480A4 EP 98923819 A EP98923819 A EP 98923819A EP 98923819 A EP98923819 A EP 98923819A EP 1003480 A4 EP1003480 A4 EP 1003480A4
Authority
EP
European Patent Office
Prior art keywords
nucleic acids
peptide nucleic
cellular uptake
enhanced cellular
conjugated peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98923819A
Other languages
English (en)
French (fr)
Other versions
EP1003480A1 (de
Inventor
Peter E Nielsen
Helle Knudsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1003480A1 publication Critical patent/EP1003480A1/de
Publication of EP1003480A4 publication Critical patent/EP1003480A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP98923819A 1997-05-28 1998-05-28 Mit peptiden konjugierte nukleinsäuren mit erhöhter aufnahme in zellen Withdrawn EP1003480A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86476597A 1997-05-28 1997-05-28
US864765 1997-05-28
PCT/US1998/010804 WO1998053801A1 (en) 1997-05-28 1998-05-28 Conjugated peptide nucleic acids having enhanced cellular uptake

Publications (2)

Publication Number Publication Date
EP1003480A1 EP1003480A1 (de) 2000-05-31
EP1003480A4 true EP1003480A4 (de) 2002-04-17

Family

ID=25344022

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98923819A Withdrawn EP1003480A4 (de) 1997-05-28 1998-05-28 Mit peptiden konjugierte nukleinsäuren mit erhöhter aufnahme in zellen

Country Status (7)

Country Link
EP (1) EP1003480A4 (de)
JP (1) JP2001501975A (de)
AU (1) AU745309B2 (de)
CA (1) CA2291839A1 (de)
IL (1) IL133087A0 (de)
NZ (1) NZ501289A (de)
WO (1) WO1998053801A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989270B1 (en) 1997-10-17 2006-01-24 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
US6472209B1 (en) 1997-10-17 2002-10-29 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
US6723560B2 (en) 1998-10-08 2004-04-20 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
DE19909373A1 (de) * 1999-03-03 2000-10-05 Ugichem Neue PNA-Monomere, daraus resultierende PNA-Oligomere und deren Verwendung
DE10038169A1 (de) * 2000-08-04 2002-03-07 November Ag Molekulare Medizin Synthetisches Partikel zur Markierung einer Substanz
EP1543019A2 (de) * 2002-09-11 2005-06-22 Santaris Pharma A/S Modifizierte pna-moleküle
CA2744987C (en) 2008-12-02 2018-01-16 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
AU2010270714B2 (en) 2009-07-06 2015-08-13 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods use thereof
EP2620428B1 (de) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetrische hilfsgruppe
SG10201700554VA (en) 2011-07-19 2017-03-30 Wave Life Sciences Pte Ltd Methods for the synthesis of functionalized nucleic acids
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
BR112015000723A2 (pt) 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd adjuvante de ácido nucléico quiral
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
EP3095461A4 (de) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäure-adjuvans mit immunitätsinduktionswirkung und immunitätsinduktionsaktivator
MX2016009290A (es) 2014-01-16 2017-02-28 Wave Life Sciences Ltd Diseño quiral.
DE102014007158A1 (de) * 2014-05-16 2015-11-19 Ugichem Gmbh Neue Peptid-Nukleinsäuren-Monomere und -Oligomere
CN111588695A (zh) 2014-06-24 2020-08-28 川斯勒佰尔公司 用于递送核酸的立体化学富集组合物
CN114502202A (zh) * 2019-07-24 2022-05-13 纽约市哥伦比亚大学理事会 用于通过使用基于肽核酸的试剂来治疗癌症的方法和组合物
CN114315835B (zh) * 2021-11-30 2023-03-03 华南农业大学 一种6-苯甲基腺嘌呤半抗原、人工抗原、抗体及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020702A1 (en) * 1991-05-24 1992-11-26 Ole Buchardt Peptide nucleic acids
WO1996004000A1 (en) * 1994-08-05 1996-02-15 The Regents Of The University Of California PEPTIDE-BASED NUCLEIC ACID MIMICS (PENAMs)
WO1996011205A1 (en) * 1994-10-06 1996-04-18 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
WO1996019240A1 (en) * 1994-12-21 1996-06-27 Novartis Ag Oligonucleotide-dendrimer conjugates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
EP0870055B1 (de) * 1995-10-12 2007-05-16 LANSDORP, Peter, M. Verfahren zum nachweis von mehrfachkopien einer wiederholungssequenz in einem nukleinsäuremolekül

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020702A1 (en) * 1991-05-24 1992-11-26 Ole Buchardt Peptide nucleic acids
WO1996004000A1 (en) * 1994-08-05 1996-02-15 The Regents Of The University Of California PEPTIDE-BASED NUCLEIC ACID MIMICS (PENAMs)
WO1996011205A1 (en) * 1994-10-06 1996-04-18 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
WO1996019240A1 (en) * 1994-12-21 1996-06-27 Novartis Ag Oligonucleotide-dendrimer conjugates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO9853801A1 *
WITTUNG, P. ET AL.: "Phospholipid Membrane Permeability of Peptide Nucleic Acid", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 365, no. 1, 22 May 1995 (1995-05-22), pages 27 - 29, XP001056078 *

Also Published As

Publication number Publication date
JP2001501975A (ja) 2001-02-13
AU7602198A (en) 1998-12-30
NZ501289A (en) 2001-06-29
IL133087A0 (en) 2001-03-19
CA2291839A1 (en) 1998-12-03
AU745309B2 (en) 2002-03-21
EP1003480A1 (de) 2000-05-31
WO1998053801A1 (en) 1998-12-03

Similar Documents

Publication Publication Date Title
IL133087A0 (en) Conjugated peptide nucleic acids having enhanced cellular uptake
PL344341A1 (en) Peptides
HUP0101532A3 (en) Improved interferon polymer conjugates
EP1012260A4 (de) Interleukin-20
GB9827348D0 (en) Natriuretic peptide
EP0977579A4 (de) Konjugate aus peptiden, die liganden von gastrinrezeptoren sind
GB2332660B (en) Improved deflector
GB9703681D0 (en) Protein complemention
GB9719879D0 (en) Protein
EP0926691A4 (de) Mehrfachschalter für kraftfahrzeug
ZA98642B (en) Immune-modulation with amino acids
GB9718110D0 (en) Peptides
GB9825854D0 (en) Peptide
EP1018551A4 (de) Megsin-protein
EP0961793A4 (de) Peptiden enthaltende polymere
GB9700154D0 (en) Peptides
GB9812675D0 (en) Peptides
ZA984322B (en) Sucrose-binding proteins
EP0996457A4 (de) Fsh freisetzende peptide
GB9720784D0 (en) Protein
GB9807890D0 (en) Peptides
GB9719486D0 (en) Electrically propelled vehicle
GB9713146D0 (en) Peptides
GB9701024D0 (en) Peptides
GB9720995D0 (en) Nucleic acids

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020306

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07K 14/00 A, 7A 61K 47/48 B, 7A 61K 9/127 B, 7A 61K 31/70 B, 7A 61K 38/00 B, 7C 07H 21/00 B, 7C 07K 1/00 B, 7C 07K 1/13 B, 7C 07K 2/00 B, 7C 12N 5/00 B, 7C 12Q 1/68 B

17Q First examination report despatched

Effective date: 20031229

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050624